The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
about
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancerChemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancerOptimal primary surgical treatment for advanced epithelial ovarian cancerUltra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancerOptimal primary surgical treatment for advanced epithelial ovarian cancerChemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancerLuteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancerClear cell carcinoma of the ovary: is there a role of histology-specific treatment?Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group studyCytoreductive Surgery in Ovarian Cancer: Why, When, and How?A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV.What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.Inherited determinants of ovarian cancer survival.Surgical management of ovarian cancer.Chemotherapy for ovarian cancer: current concepts.Survival prediction based on inherited gene variation analysisCan primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?Cytoreductive surgery for advanced stages of ovarian cancer.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian CancerNeoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.Inherited variants in regulatory T cell genes and outcome of ovarian cancer.Prognosis and conditional disease-free survival among patients with ovarian cancerPolymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.Assessment of hepatocyte growth factor in ovarian cancer mortality.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerPreoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer.Medical treatment of epithelial ovarian cancer.The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma.The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
P2860
Q24193930-98A28673-8407-4849-8B5C-75853E0C1E21Q24201686-B9788508-2762-4C47-A77B-CF7EF72C332DQ24234923-20B52368-D8BB-4A15-81B0-5850C96CC781Q24235043-D8ADAAD9-B3E8-4D69-B6B8-F3773E5B9B75Q24242510-D8CAC99E-FB90-48E3-AFE9-F3347D106EAEQ24242912-74CF7F71-6379-4669-8DB3-4AE7221C8017Q26471403-BEFC39F0-51B5-4A63-8009-D541BDF76FE4Q27012348-BA4A8D64-1F06-470B-A871-D8F96833E75AQ30359038-0A24D6C5-EBC9-412B-ADBA-273A993A1091Q30360249-1DB009CA-7B73-42AC-A589-15852A411B52Q30418957-AEF0EE6D-C2B2-4C5B-8F83-01FF1F240E41Q30419554-0035CC0F-AECB-42F6-AA33-3271C69748BFQ30866485-9521F504-1B45-499F-9D24-8F559EDF2354Q31141618-9B48F031-CCCA-412E-B7FA-930241C0AB54Q31143363-D7E11FAD-0237-42FD-84E9-D408699CD0C5Q33638923-D38678A8-0C4D-4167-811C-7C712BDB2960Q33742791-2FF655B5-E12C-4CE3-843F-BC869CB73C18Q33742794-36B427A0-1043-4B0A-A810-EA46EE81BDA7Q33745031-36EA39E2-ED89-4D14-BE8B-757CEC2287A1Q33748934-54ECFF3C-9F06-4BD5-B885-BA78F9F49016Q33959827-1318BEFC-F03F-4D3D-AA69-CB58226DF840Q34121226-B49A5DDF-E0BC-49C7-B43B-D47F0D4F3F69Q34196183-B528B0E3-3AD1-44F7-89B8-0DD861C9111CQ34389383-0D4BFEF2-C234-4275-AF89-CFD7AA636243Q34575290-4213F618-1A03-450F-B418-90406F76B359Q34692286-18A90E3F-A3C2-41DA-A35D-AC36CD5B4EB5Q35031998-9C3CB2FD-910C-4065-BAA7-07AAB889F0A6Q35058278-0F7199E8-CDC1-47A0-BCA0-9AA1819BACEBQ35156876-78DE8144-9254-4C13-AFEA-1ED47DB0895CQ35730375-5DA1674D-4FAE-44CB-872F-1AA6DBD5DC3EQ35758709-1381FCD0-9058-4FD1-ABC6-ABBD5C5F1B94Q35987782-93BFE073-B2DB-4D22-B87E-9148823910BAQ36089005-8CEE6D03-E8D5-43CC-9D9E-590300B8C459Q36443934-006C9150-420A-42DB-928F-4800B292B33CQ36598896-9CB8F55C-8165-4B34-831B-E5DE025CCC42Q36758929-A3C9EEC8-BEAC-4D39-ABE4-2151F9E8BCC1Q36830674-A2FC955C-7347-4D74-9CCC-FD9B46D20741Q36850922-9AF6D9E5-455C-4A6D-BD54-66F9E47BEA79Q36979335-F4D210C7-354B-4AC0-ADEE-65E9FA4B4D43Q37017000-EF7F35B9-20D9-4710-93B5-0FC7F39C5300
P2860
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The influence of cytoreductive ...... ecologic Oncology Group study.
@ast
The influence of cytoreductive ...... ecologic Oncology Group study.
@en
type
label
The influence of cytoreductive ...... ecologic Oncology Group study.
@ast
The influence of cytoreductive ...... ecologic Oncology Group study.
@en
prefLabel
The influence of cytoreductive ...... ecologic Oncology Group study.
@ast
The influence of cytoreductive ...... ecologic Oncology Group study.
@en
P2093
P1433
P1476
The influence of cytoreductive ...... ecologic Oncology Group study.
@en
P2093
P304
P356
10.1016/0090-8258(92)90100-W
P407
P577
1992-11-01T00:00:00Z